Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer
Namrata S. Patil, Barzin Y. Nabet, Sören Müller et al. · Cancer Cell · 2022
Cited by 408 works. doi:10.1016/j.ccell.2022.02.002
Authors
- Namrata S. Patil
- Barzin Y. Nabet
- Sören Müller
- Hartmut Koeppen
- Wei Zou
- Jennifer Margaret Giltnane
- Amelia Au‐Yeung
- Shyam Srivats
- Jason H. Cheng
- Chikara Takahashi
- Patricia E. de Almeida
- Avantika S. Chitre
- Jane L. Grogan
- Linda K. Rangell
- Sangeeta K. Jayakar
- Maureen Peterson
- Allison W. Hsia
- William E. O’Gorman
- Marcus D. Ballinger
- Romain Banchereau
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- Integrating single-cell transcriptomic data across different conditions, technologies, and species
- The Molecular Signatures Database Hallmark Gene Set Collection
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Software for Computing and Annotating Genomic Ranges
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells